BACKGROUND: Membranous nephropathy (MGN) remains the most common cause of adult onset nephrotic syndrome, and within the primary glomerulonephritis group is a leading cause of renal failure. A complete remission (CR) confers an excellent long-term prognosis, but the quantitative benefits of partial remissions (PR) have not been defined. METHODS: This study evaluated the rate of renal function decline (slope), relapse, and renal survival in nephrotic MGN patients with CR, PR, or no remission (NR). Multivariate analysis included clinical and laboratory data at presentation and over follow-up, blood pressure control and agents employed, and immunosuppressive therapy. RESULTS: The study cohort consisted of 348 nephrotic MGN patients with a minimum of 12 months follow-up identified from the Toronto Glomerulonephritis Registry. Over a median follow-up of 60 months, 102 experienced a CR, 136 had a PR, and 110 had no remission. A PR was independently predictive of slope and survival from renal failure by multivariate analysis (hazard ratio 0.08, 95% CI 0.03-0.19, P < 0.001). Benefit from immunosuppression could only be shown in a subset of high-risk patients. Treatment-related PR had the same long-term implication as spontaneous ones. Relapses from PR were high (47%) but often reversible. CONCLUSION: A partial remission is an important therapeutic target with implications for both progression rate and renal survival.
BACKGROUND:Membranous nephropathy (MGN) remains the most common cause of adult onset nephrotic syndrome, and within the primary glomerulonephritis group is a leading cause of renal failure. A complete remission (CR) confers an excellent long-term prognosis, but the quantitative benefits of partial remissions (PR) have not been defined. METHODS: This study evaluated the rate of renal function decline (slope), relapse, and renal survival in nephrotic MGNpatients with CR, PR, or no remission (NR). Multivariate analysis included clinical and laboratory data at presentation and over follow-up, blood pressure control and agents employed, and immunosuppressive therapy. RESULTS: The study cohort consisted of 348 nephrotic MGNpatients with a minimum of 12 months follow-up identified from the Toronto Glomerulonephritis Registry. Over a median follow-up of 60 months, 102 experienced a CR, 136 had a PR, and 110 had no remission. A PR was independently predictive of slope and survival from renal failure by multivariate analysis (hazard ratio 0.08, 95% CI 0.03-0.19, P < 0.001). Benefit from immunosuppression could only be shown in a subset of high-risk patients. Treatment-related PR had the same long-term implication as spontaneous ones. Relapses from PR were high (47%) but often reversible. CONCLUSION: A partial remission is an important therapeutic target with implications for both progression rate and renal survival.
Authors: Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim Journal: J Am Soc Nephrol Date: 2016-10-18 Impact factor: 10.121
Authors: Marie C Hogan; Heather N Reich; Peter J Nelson; Sharon G Adler; Daniel C Cattran; Gerald B Appel; Debbie S Gipson; Matthias Kretzler; Jonathan P Troost; John C Lieske Journal: Kidney Int Date: 2016-08-12 Impact factor: 10.612
Authors: Sean J Barbour; Daniel C Cattran; Gabriela Espino-Hernandez; Michelle A Hladunewich; Heather N Reich Journal: Kidney Int Date: 2015-08-19 Impact factor: 10.612
Authors: Saskia F Heeringa; Clemens C Möller; Jianyang Du; Lixia Yue; Bernward Hinkes; Gil Chernin; Christopher N Vlangos; Peter F Hoyer; Jochen Reiser; Friedhelm Hildebrandt Journal: PLoS One Date: 2009-11-10 Impact factor: 3.240